Literature DB >> 19728715

(3R,5S,7as)-(3,5-Bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol, a novel neuroprotective agent.

Kelly E Desino1, Sabah Ansar, Gunda I Georg, Richard H Himes, Mary Lou Michaelis, Douglas R Powell, Emily A Reiff, Hanumaiah Telikepalli, Kenneth L Audus.   

Abstract

Compounds that interact with microtubules, such as paclitaxel, have been shown to possess protective properties against beta-amyloid (Abeta) induced neurodegeneration associated with Alzheimer's disease. In this work, the novel agent (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol was investigated for effectiveness in protecting neurons against several toxic stimuli and its interaction with the microtubule network. Exposure of neuronal cultures to Abeta peptide in the presence of 5 nM (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol resulted in a 50% increase in survival. Neuronal cultures treated with other toxic stimuli such as staurosporine, thapsigargin, paraquat, and H(2)O(2) showed significantly enhanced survival in the presence of (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol. Microtubule binding and tubulin assembly studies revealed differences compared to paclitaxel but confirmed the interaction of (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol with microtubules. Furthermore, in vitro studies using bovine brain microvessel endothelial cells experiments suggest that (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol can readily cross the blood-brain barrier in a passive manner.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19728715      PMCID: PMC2788673          DOI: 10.1021/jm900254k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  29 in total

Review 1.  Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases.

Authors:  M Y Sherman; A L Goldberg
Journal:  Neuron       Date:  2001-01       Impact factor: 17.173

2.  A fluorescence-based high-throughput assay for antimicrotubule drugs.

Authors:  Donna M Barron; Sabarni K Chatterjee; Rudravajhala Ravindra; Rebecca Roof; Erkan Baloglu; David G I Kingston; Susan Bane
Journal:  Anal Biochem       Date:  2003-04-01       Impact factor: 3.365

3.  Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons.

Authors:  Guibin Li; Alexander Faibushevich; Brandon J Turunen; Sung Ok Yoon; Gunda Georg; Mary L Michaelis; Rick T Dobrowsky
Journal:  J Neurochem       Date:  2003-01       Impact factor: 5.372

4.  Amyloid peptide toxicity and microtubule-stabilizing drugs.

Authors:  Mary L Michaelis; Yingxue Chen; Sarah Hill; Emily Reiff; Gunda Georg; Antonie Rice; Kenneth Audus
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

Review 5.  Structure-brain exposure relationships.

Authors:  Stephen A Hitchcock; Lewis D Pennington
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

6.  Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

Authors:  Kelly M Mahar Doan; Joan E Humphreys; Lindsey O Webster; Stephen A Wring; Larry J Shampine; Cosette J Serabjit-Singh; Kimberly K Adkison; Joseph W Polli
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

7.  Apoptotic neuronal cell death induced by the non-fibrillar amyloid-beta peptide proceeds through an early reactive oxygen species-dependent cytoskeleton perturbation.

Authors:  Isabelle Sponne; Alexandre Fifre; Béatrice Drouet; Christophe Klein; Violette Koziel; Martine Pinçon-Raymond; Jean-Luc Olivier; Jean Chambaz; Thierry Pillot
Journal:  J Biol Chem       Date:  2002-11-14       Impact factor: 5.157

8.  Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation.

Authors:  Katsutoshi Furukawa; Yue Wang; Pamela J Yao; Weiming Fu; Mark P Mattson; Yasuto Itoyama; Hiroshi Onodera; Ian D'Souza; Parvone H Poorkaj; Thomas D Bird; Gerard D Schellenberg
Journal:  J Neurochem       Date:  2003-10       Impact factor: 5.372

9.  Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease.

Authors:  E A Grace; C A Rabiner; J Busciglio
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

10.  Fine structural localization of a blood-brain barrier to exogenous peroxidase.

Authors:  T S Reese; M J Karnovsky
Journal:  J Cell Biol       Date:  1967-07       Impact factor: 10.539

View more
  2 in total

1.  Synthesis and ring-chain-ring tautomerism of bisoxazolidines, thiazolidinyloxazolidines, and spirothiazolidines.

Authors:  Cecilia Saiz; Peter Wipf; Graciela Mahler
Journal:  J Org Chem       Date:  2011-06-14       Impact factor: 4.354

2.  The quest for a simple bioactive analog of paclitaxel as a potential anticancer agent.

Authors:  David G I Kingston; James P Snyder
Journal:  Acc Chem Res       Date:  2014-07-23       Impact factor: 22.384

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.